Incyte (NASDAQ: INCY) reported Q1 EPS of $0.12, $0.08 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $263 million versus the consensus estimate of $263.97 million.

2016 Financial Guidance

The Company has updated its full year 2016 financial guidance, as detailed below.

		Incyte		ARIAD EU		Combined
Jakafi net product revenues		$815-$830 million(previously $800-$815 million)		-		$815-$830 million
Iclusig net product revenues		-		$25-$30 million		$25-$30 million
Research and development expenses		$620-$640 million(no change)		$15-$20 million		$635-$660 million
Selling, general and administrative expenses		$255-$275 million(previously $255-$270 million)		$30-$35 million		$285-$310 million

For earnings history and earnings-related data on Incyte (INCY) click here.